

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, ... , Marcela V. Maus, Carl H. June

JCI Insight. 2019;4(4):e127684. <https://doi.org/10.1172/jci.insight.127684>.

Corrigendum

Original citation: *JCI Insight.* 2018;3(8):e120505. <https://doi.org/10.1172/jci.insight.120505> Citation for this corrigendum: *JCI Insight.* 2019;4(4):e127684. <https://doi.org/10.1172/jci.insight.127684> In Table 1, the responses given for patients 1 and 6 are incorrect. The correct responses as well as the definition for SCR are below. Patient 1, SCR Patient 6, PD SCR, stringent complete response. The article has been updated to reflect these changes. The authors regret the errors.

Find the latest version:

<https://jci.me/127684/pdf>



Corrigendum

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, Edward A. Stadtmauer, Wei-Ting Hwang, Simon F. Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P. Carroll, William H. Matsui, Qiuju Wang, Madhav V. Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T. Vogl, Brendan M. Weiss, Adam D. Cohen, Patricia A. Mangan, Emily C. Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M. Davis, Anne Lamontagne, Karen Dengel, Naseem D.S. Kerr, Regina M. Young, Donald L. Siegel, Bruce L. Levine, Michael C. Milone, Marcela V. Maus, and Carl H. June

Original citation: *JCI Insight*. 2018;3(8):e120505. <https://doi.org/10.1172/jci.insight.120505>.

Citation for this corrigendum: *JCI Insight*. 2019;4(4):e127684. <https://doi.org/10.1172/jci.insight.127684>.

In Table 1, the responses given for patients 1 and 6 are incorrect. The correct responses as well as the definition for SCR are below.

Patient 1, SCR

Patient 6, PD

SCR, stringent complete response.

The article has been updated to reflect these changes.

The authors regret the errors.